Build your own keyword analysis with our tools
SEO Report
Server Infos
Backlinks

HTML Analysis

Page Status
 

Found

Highlighted Content
Title

Alexion Pharmaceuticals - Alexion Pharmaceuticals | Innovators in Complement Inhibition

Description

Combines groundbreaking science with a steadfast commitment to meeting the needs of patients living with severe, life-threatening and often ultra-rare diseases

Keywords

Alexion, Alexion Pharmaceuticals, pharmaceutical company, biotech, biotechnology, biotech company, biotechnology company, rare disease, rare diseases, ultra rare disease, ultra rare diseases, ultra-rare disease, ultra-rare diseases, orphan drug, orphan drugs, orphan disease, orphan diseases, pharmaceutical research, medical product, drug manufacturer, medical research; soliris, pnh, paroxysmal nocturnal hemoglobinuria, alexion, pnh treatment, pnh information, pnh research, pnh management, pnh therapy, pnh symptoms, pnh signs, thrombosis, ldh levels, hemolysis, aHUS, atypical hemolytic uremic syndrome, hematologic disease, kidney disease, transplant, cancer, autoimmune disorders, eculizumab, complement inhibition

H1

Alexion Pharmaceuticals

H2

Highlights
News
Events

H3

Dr. Martin Mackay Appears on "BioCentury This Week" to Discuss Breakthrough Therapy Designation for Asfotase Alfa for the Treatment of Patients with Hypophosphatasia
Alexion Breaks Ground On New Global Headquarters
Alexion Expands Leadership Team
Delivering Life-Transforming Therapies

H4

H5

Text Analysis

Cloud of Keywords from all content
High relevance
 

alexion global thursday july pharmaceuticals

Medium relevance
 

patients treatment news eculizumab team soliris june leadership

Low relevance
 

treatment news eculizumab team soliris june leadership orphan including optica hpp nmo neuromyelitis ultra-rare headquarters life-transforming r&d president tuesday report life-threatening executive alexion’s soliris® receives conference martin careers quarter pnh investors healthcare mackay therapy asfotase designation alfa hypophosphatasia

Very Low relevance
 
orphan including optica hpp nmo neuromyelitis ultra-rare headquarters life-transforming r&d president tuesday report life-threatening executive alexion’s soliris® receives conference martin careers quarter pnh investors healthcare mackay therapy asfotase designation alfa hypophosphatasia excited broaden strengthen continued worldwide serve growth officer prepare portfolio islam senior saqib sachs 34th chief strategy annual safety delivering prescribing goldman serves positive additions events wells opinion committee products medicinal drug fargo stories countries platform operations therapies strive impact disorders severe lives wednesday haven’s candidates first-in-class targeted therapeutic innovative underway highly enzyme replacement metabolic disorder inherited trials phase clinical programs development legal sitemap contact inhibition innovators complement ahus highlights breakthrough lead discuss week appears biocentury leads progressive building downtown office laboratory 11-story state-of-the-art crossing urban occupancy expands open expected revitalization effort years founded destruction deformity organs vital damage multiple bones watch return city marks conn breaks ground pleased

Highlighted Content Analysis

Cloud of Keywords from all content
High relevance
 

alexion

Medium relevance
 

pharmaceuticals

Low relevance
 

pharmaceuticals patients

Very Low relevance
 
patients orphan disease orphan drugs orphan diseases orphan drug medical product medical research; soliris drug manufacturer ultra-rare diseases pharmaceutical research ultra rare diseases biotech company biotechnology biotech biotechnology company rare disease pnh ultra rare disease rare diseases ultra-rare disease pnh treatment kidney disease hematologic disease atypical hemolytic uremic syndrome ahus transplant cancer complement inhibition eculizumab autoimmune disorders hemolysis ldh levels pnh research pnh information pharmaceutical company pnh management pnh therapy thrombosis pnh signs pnh symptoms paroxysmal nocturnal hemoglobinuria life-transforming diseases ultra-rare life-threatening severe highlights news mackay martin events living meeting inhibition complement innovators combines groundbreaking commitment steadfast science appears biocentury headquarters global ground expands leadership therapies delivering team breaks hypophosphatasia breakthrough discuss week therapy designation treatment alfa asfotase alexion pharmaceuticals